Results for acetylcholinesterase translation from English to Lithuanian

in vitro, this metabolite shows minimal inhibition of acetylcholinesterase ( 10%) .
in vitro nustatyta, kad sis metabolitas labai silpnai slopina acetilcholinesteraz ( 10%) .

rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
rivastigminas blokuoja fermentus, kurie skaldo acetilcholiną: acetilcholinesterazę ir butirilcholinesterazę.

analyses of acetylcholinesterase (ache) may also be performed on these samples, if deemed appropriate.
taip pat galima tirti acetilcholinesterazę (ache).

the active substance in rivastigmine 3m health care ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
veiklioji rivastigmine 3m health care ltd medžiaga rivastigminas blokuoja acetilcholiną skaidančių fermentų acetilcholinesterazės ir butirilcholinesterazės veiklą.

as rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.
rivastigmino pusins eliminacijos periodas yra apie 1 val., o acetilcholinesterazs inhibicija trunka mazdaug 9 valandas, todl, jei perdozavimas kliniskai nepasireiskia, rekomenduojama 24 valandas nevartoti rivastigmino.

in healthy young men, an oral 3 mg dose decreases acetylcholinesterase (ache) activity in csf by approximately 40% within the first 1.5 hours after administration.
sveikiems jauniems vyrams geriamoji 3 mg vaisto doz apie 40% sumazina acetilcholinesterazs (ache) aktyvum likvore per pirmsias 1, 5 valandas po vartojimo.

a meta-analysis of patients with moderate to severe alzheimer 's disease (mmse total scores 20) from the six phase iii, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
21 sesi iii fazs 6 mnesi trukms kontrolini (poveikis lygintas su placebo sukeliamu) tyrim, kuriuose dalyvavo vidutinio sunkumo arba sunkia alzheimerio liga (pries gydym mmse skals bendras bal skaicius buvo 20) sergantys ligoniai (skaitant vartojusius vien memantino arba vien nekintam doz acetilcholinesterazs inhibitoriaus) , meta analizs duomenys rodo, kad pazinimo, bendrosios bkls ir funkcijos tyrim duomenims memantinas dar statistiskai reiksmingesn poveik.